
    
      To compile characteristics of real-world outcomes of Boston Scientific Corporation's
      commercially approved VerciseTM Deep Brain Stimulation (DBS) Systems for the treatment of
      dystonia.

      Subjects' improvement in disease symptoms and overall Quality of life will be assessed.
    
  